Brii Bio­sciences snaps up VBI Vac­ci­nes' HBV pro­grams in ex­pand­ed deal, jump­ing in­to com­mer­cial mode

Five years af­ter bag­ging Chi­na rights to VBI Vac­cines’ he­pati­tis B ther­a­py and team­ing up on its de­vel­op­ment, Brii Bio­sciences is go­ing for the whole thing.

In an ex­pand­ed deal, Brii has de­cid­ed to ac­quire world­wide rights to VBI-2601, an im­munother­a­peu­tic can­di­date al­so known as BRII-179. Al­so part of the pact: Pre­Hevbrio, VBI’s re­com­bi­nant HBV vac­cine, for which Brii will now get an ex­clu­sive li­cense in the Asia-Pa­cif­ic re­gion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER